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Pediatric Thyroid Disease: When is Surgery




In tro duc ti on
Surgical diseases of the thyroid in the pediatric population
represent a diverse set of both benign and malignant conditions.
Benign conditions include Graves’ disease, toxic adenomas,
congenital hyperthyroidism, and goiter. Malignancy is most
commonly differentiated thyroid cancers (DTC), which includes
papillary (predominantly) and follicular cancers, and medullary
thyroid cancer (MTC), with its related familial cancer syndromes.
All surgical diseases of the thyroid are rare in children.
Benign Thyroid Conditions that May Require Surgical 
Intervention 
Graves’ disease is an autoimmune condition which causes
hyperthyroidism or thyrotoxicosis secondary to the production of
autoantibodies to the thyroid-stimulating hormone (TSH)
receptor. The incidence of Graves’ disease in the pediatric
population is approximately 1 per 100 000 per year. This
represents 0.1 per 100 000 in the child and 3 per 100 000 in the
adolescent population (1). Children with Graves’ disease should
be managed with methimazole, and the dose should be adjusted
until the patient is rendered biochemically euthyroid and the
symptoms of Graves’ disease are relieved; beta-blockers can be
added for the cardiovascular sequelae. The use of propylthiouracil
(PTU) for management of Graves’ disease in children is
prohibited due to the higher incidence of liver failure, which
recently led the U.S. Food and Drug Administration (FDA) to issue
a warning against the use of PTU for the treatment of Graves’
disease in children (and adults). Children on methimazole should
be monitored for side effects including skin rash, joint and
muscle pain, fever, and agranulocytosis. If side effects develop,
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methimazole should be discontinued immediately. When
methimazole is chosen as the first-line treatment for Graves’
disease in children, it should be administered for one to two
years and then discontinued, or reduced, in order to assess
whether the patient is in remission. For patients who cannot be
managed with methimazole or who fail to undergo remission,
consideration should be given to definitive treatment with
surgery or radioactive iodine.
Numerous studies have reported a failure of anti-thyroid
drugs (ATD) to produce a lasting remission and to provide a
euthyroid state for children with Graves’ disease. In a 25-year
retrospective analysis, Hamburger reported that only 59 of 182
(32%) pediatric and adolescent patients with Graves’ disease
initially treated with ATD achieved a euthyroid state and lasting
remission. The remaining 68% of patients ultimately progressed
to definitive therapy with either radioactive iodine or surgery (2).
In another retrospective review of 184 children receiving ATD for
Graves’ disease, only 28% were able to achieve remission
within two years of starting pharmacologic treatment;  53% of
patients eventually went on to receive radioactive iodine or
undergo thyroidectomy (3). In younger children, the response
rate to medical therapy is less robust. In two analyses of pre-
pubescent and pubescent children receiving ATD for Graves’
disease, pre-pubescent children were able to achieve lasting
disease remission in only 17% of cases after an average of 3.5
years of therapy, and 33% after an average of six years of
therapy (4,5). The overwhelming majority of children with
Graves’ disease ultimately require definitive management.
Concerns regarding the safety of radioactive iodine therapy
in children stem from several studies. In a population-based
analysis of 7 417 patients over 41 years, Franklyn et al (6) noted
an overall decrease in the incidence of cancers and cancer-
specific mortality in hyperthyroid patients who received
radioactive iodine; however, there was a significant increase in
TC incidence and deaths attributed to TC. A similar multi-
institutional retrospective analysis of 21 000 individuals treated
with radioactive iodine observed that while mortality from all
cancers was not statistically different from the rate expected
after 10 years of follow-up, TC incidence and TC-related mortality
were nearly four times higher than expected. However, no TC
were identified in patients treated with radioactive iodine before
age 20 (7). In another study of 107 patients younger than age 20
years treated with radioactive iodine, not a single thyroid or
hematopoietic malignancy was identified, even though many of
the patients did not undergo ablative therapy (8).
The risk of radiation exposure, however, is age- and dose-
dependent (9). Thus, the risk is greatest for young children with
large goiters. Accordingly, radioactive iodine is a better option for
older children with smaller glands. 131I therapy should be
avoided in very young children (age <5 years). 131I  therapy in
patients between 5 and 10 years of age is generally acceptable
if the calculated 131I administered activity is <10 mCi. 131I
therapy in patients older than 10 years is acceptable if the
activity is >150 µCi/g of thyroid tissue.
The potential association between the development of
parathyroid hyperplasia and hyperparathyroidism after
radioactive iodine therapy is another point of controversy.
Schneider et al (10) evaluated 4296 patients (mean age 8.5
years, standard deviation 12.8 years) who underwent external
beam radiation to the head and neck. This study showed an
incidence of hyperparathyroidism approaching 5% at 50 years in
a dose-dependent manner, and also showed that patients
exposed at a younger age had the highest risk for developing the
disease (10). A strong association between radiation exposure
and hyperparathyroidism also has been seen in several adult
case series (11,12). However, two recent large cohort studies
have disputed these results. No increased incidence of
hyperparathyroidism was observed in 3 440 individuals who
grew up in proximity to the Hanford Nuclear site (13), or in a
Swedish cohort of children and adolescents (mean age 7.4
years) treated with radioactive iodine for thyrotoxicosis (14).
Surgery is an acceptable form of therapy for pediatric Graves‘
disease. Thyroid surgery should be chosen when definitive
therapy for Graves’ disease is indicated, and the child is too
young for 131I or the required dose of 131I is too high. The
operation of choice is total or near-total thyroidectomy,
performed with the intent of rendering the patient hypothyroid.
Subtotal thyroidectomy should be avoided due to an
unacceptably high incidence of recurrence.  In order to avoid the
possibility of hemodynamic instability or thyroid storm in the
operating room, children with Graves’ disease undergoing
thyroidectomy should be euthyroid prior to surgery, and
methimazole with/out beta-blockers given as necessary.
Methimazole is typically given for one to two months in
preparation for thyroidectomy. Potassium iodide should be given
in the immediate preoperative period. Ten days prior to surgery,
potassium iodide (SSKI; 50 mg iodide/drop) can be given as 3-7
drops (i.e., 0.15 to 0.35 mL) three times daily for 10 days prior to
surgery. Beta-blockers also may be needed in patients with
persistent tachycardia or allergy to methimazole. 
Graves’ patients who undergo thyroidectomy are more likely
to suffer from hypocalcemic complications compared to patients
who undergo thyroidectomy for other indications (e.g. cancer)
(15). There are multiple hypotheses for this finding, including
hungry bone syndrome, increased secretion of calcitonin as a
result of thyroid manipulation, and increased vascularity and
inflammation of the gland which may cause bleeding that can
obscure the operative field or result in direct adhesions to the
parathyroid glands. At our institution, calcitriol (25-50 μg twice
per day) is started three days preoperatively as prophylaxis for
post-operative hypocalcemia.
The most common risks of thyroidectomy include recurrent
laryngeal or superior laryngeal nerve injury and
hypoparathyroidism, any of which may be temporary or
permanent. Other less common risks include bleeding, which
can occur up to 72 hours after the time of surgery, and wound
infection. The largest published series of thyroidectomies for
Graves’ disease in children and adolescents included 78 children
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from the Mayo Clinic over 17 years (16). In this large, single-
institution series from a high-volume endocrine surgery center,
96% of patients achieved a permanently hypothyroid state, and
none sustained the potential complications of permanent
hypocalcemia or permanent recurrent laryngeal nerve injury.
Surgical pathology revealed an occult neoplasm in 6% of the
patients. In another series of 15 pediatric patients who
underwent thyroidectomy for benign thyroid disease (12 for
Graves’), a hypothyroid state was achieved in all patients, with
one case (6%) of permanent hypocalcemia, and no recurrent
laryngeal nerve injuries (17). These results are similar to those in
adult patients treated by high-volume endocrine surgeons (18).
In a cross-sectional analysis of the Health Care Cost and
Utilization Project Nationwide Inpatient Sample (HCUP-NIS), an
endocrine-specific complication rate of 5.9% was shown for
children undergoing thyroidectomy for benign disease when the
procedure was performed by high-volume thyroid surgeons (19).
Practice guidelines regarding the management of
hyperthyroidism and other causes of thyrotoxicosis were issued
by the American Thyroid Association (ATA) and the American
Association of Clinical Endocrinologists in 2011(20); in these
guidelines, there is a section committed to the pediatric patient.
In a study by Read et al (8), radioactive iodine produced
permanent hypothyroidism in 94% of patients, compared to 96-
100% for surgery. The long-term complications of radioactive
iodine are unclear, while the major complication of pediatric
thyroidectomy for Graves’ disease has been demonstrated to be
permanent hypocalcemia, occurring in 0-6% of cases, in
addition to the risk of recurrent laryngeal nerve injury and
postoperative hemorrhage. The authors recommended total
thyroidectomy for young patients (<5 years) and those with large
goiters (>80g), and radioactive iodine for teenage patients with
normal-sized glands. For other patients, the decision for surgery
or radioactive iodine should be made by patients and their
families, informed by surgeons, endocrinologists, and
pediatricians.
Another benign pediatric thyroid disease that can
necessitate surgery is a toxic adenoma, or “hot nodule‟. Toxic
adenomas are autonomously functioning benign tumors that
cause symptomatic hyperthyroidism. The true incidence of toxic
adenomas in children is too low for accurate epidemiologic
estimates (21). In the case of children with solitary or unilobar
toxic adenomas, thyroid lobectomy is the recommended
procedure (or rarely, isthmusectomy, if the toxic nodule is in the
isthmus) (22). Subtotal lobectomy or nodulectomy are not
adequate resections and increase the risk of recurrence. As in
the case of Graves’ disease, these patients should be rendered
biochemically and clinically euthyroid prior to surgery. The risk of
lobectomy includes bleeding and recurrent laryngeal nerve injury. 
Hyperthyroidism can also be due to congenital causes. In
1982, Leclere et al (23) identified four generations of a French
family affected by toxic thyroid hyperplasia in the absence of
TSH-receptor or thyroperoxidase antibodies and without
lymphocytic infiltration on pathology. The authors described the
new syndrome as “familial non-autoimmune hyperthyroidism”
(23). Subsequently, numerous constitutively active TSH-receptor
gene mutations have been identified (24,25). These mutations
may exist as germline mutations and present as toxic
multinodular goiters, or they may represent de novo
heterozygous point mutations contained within solitary toxic
adenomas. TSH-receptor mutations are notoriously resistant to
treatment with ATDs. Therefore, near-total or total thyroidectomy
is the treatment of choice. Non-autoimune hyperthyroidism
should be suspected in patients with a known family history, or
with persistent neonatal or early childhood hyperthyroidism
refractory to medical therapy. Genetic testing is available in these
cases (26).
A third benign thyroid disease that can require surgical
intervention is congenital goiter. Congenital goiters can be
uninodular or multinodular. Once again, the true incidence of
these pathologies is low enough to preclude epidemiologic
estimates (21). Large goiters can be symptomatic. If a patient
develops symptoms of compression related to mass effect,
such as discomfort or pain (“globus sensation‟), dysphagia,
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Tab le 1. American Thyroid Association (ATA) risk level and prophylactic thyroidectomy testing and therapy 
ATA risk level Age of RET testing Age of required Age of required Age of 
first US first serum Ct prophylactic surgery
D ASAP and within the ASAP and within the 6 months, if surgery not ASAP and within the
1st year of life 1st year of life already done 1st year of life 
C <3-5 years >3-5 years >3-5 years Before age 5 years 
B <3-5 years >3-5 years >3-5 years Consider surgery before age 5 years 
May delay surgery beyond age 5 
years if stringent criteria are meta
A <3-5 years >3-5 years >3-5 years May delay surgery beyond age 5 years
if stringent criteria are meta
a: A normal annual basal ± stimulated* serum Ct, normal annual neck US, less aggressive, MTC family history, and family reference, ASAP: as soon as possible
dysphonia,  or difficulty in breathing particularly when lying flat,
surgery should be considered. Uninodular goiters are amenable
to lobectomy, while multinodular goiters require near-total or
total thyroidectomy.
Thyroid Malignancies Uniformly Require Surgical 
Intervention 
Thyroid nodules occur rarely in children but require
investigation because the incidence of malignancy is higher in
the pediatric population than in adults (27). Evaluation of a
thyroid nodule should begin with a history and physical
examination, along with a biochemical evaluation. This is
typically followed by an ultrasound. In patients who are
hyperthyroid, ultrasound should be followed by a nuclear
medicine (“uptake‟) scan in order to determine if the pathology
is a “warm‟ or “hot‟ nodule (that is, a toxic adenoma).
Suspicious nodules should undergo interrogation with an
ultrasound-guided fine-needle aspiration (FNAB). If the
evaluation of a thyroid nodule reveals an FNAB with cytology
that is consistent with follicular or Hürthle cell neoplasia, surgical
excision is warranted for definitive histologic diagnosis; cytology
cannot identify vascular or capsular invasion and discriminate
adenomas from carcinomas. There are no specific professional
society guidelines addressing the approach to follicular or
Hürthle cell neoplasms in children. In these cases, we
recommend thyroid lobectomy with completion thyroidectomy
if the pathology demonstrates vascular and/or capsular invasion,
except in the case of bilateral nodularity, where a near-total or
total thyroidectomy is warranted initially. Malignant lesions
should be managed as described below.
According to the most recent published data from the
Surveillance, Epidemiology and End Results (SEER) database,
the age-adjusted annual incidence of thyroid cancer in the United
States is 0.54 per 100 000 per year (28). Incidence of DTC is
0.49 per 100 000 per year, but is rising steeply, largely because
of the rapid expansion of papillary thyroid cancer that has been
observed around the world. Compared to adults, pediatric
patients with DTC present with more extensive disease; lymph
node involvement at the time of diagnosis is seen in 40-80% of
children compared to 20-50% of adults. Children present with
distant metastases in 20-30% of cases (29). Nevertheless,
prognosis is favorable, with an associated 5-year survival of 95-
99%, and a 20-year survival of 90% (30). Owing to the relative
rarity of DTC in children, there have been no prospective
randomized clinical trials to determine optimal management. 
The Surgical Disciplines Committee of the Children’s Cancer
Groups has published two studies advocating for extensive
surgical resection at the time of diagnosis. In a retrospective
review of 329 patients diagnosed with DTC prior to age 21, the
investigators found that progression-free survival was inversely
associated with age and directly associated with the presence
of residual cervical disease after surgery (31). In a follow-up
study of 83 patients from the original cohort who presented with
metastatic disease at the time of diagnosis, the investigators
noted that the 10-year overall survival was 100%. All of the
patients in this subgroup received radioactive iodine in the
adjuvant setting (32). In a similar study of 235 patients
diagnosed with DTC before age 18, Handkiewicz-Junak et al (33)
demonstrated that anything less than a total thyroidectomy was
associated with an increased risk of local recurrence in the
thyroid bed. When thorough lymphadenectomy was performed
in conjunction with near-total or total thyroidectomy, patients
with clinically or radiographically positive lymph nodes achieved
survival rates that were similar to those of patients who
presented with node-negative disease. In this particular case,
the authors defined lymph node management as “complete” if
it included a modified radical neck dissection (33).
Moreover, PTC is frequently multifocal and bilateral within
the thyroid gland; therefore, near-total or total thyroidectomy is
usually indicated. This operative approach further facilitates the
administration of radioactive iodine post-operatively and long-
term surveillance with thyroglobulin (Tgb) levels. Data also show
that risk of recurrence and even survival are enhanced
statistically with near-total or total thyroidectomy compared to
lobectomy in adults (34). Consequently, there is growing
consensus that children with DTC should undergo total or near-
total thyroidectomy with central compartment lymph node
dissection for clinically or radiographically positive lymph node
disease (29). 
Notably, there is little regarding the management of DTC in
children among current practice guidelines; only the British
Thyroid Association among the major international professional
societies specifically addresses the management of DTC in the
pediatric population with the broad-based recommendation that
“the general principles of management are similar to those in
adults” (35). 
MTC arises from the calcitonin-producing parafollicular C
cells of the thyroid gland. It has an incidence in children of 0.03
per 100 000 population per year. MTC can occur sporadically or
as part of a spectrum of familial MTC syndromes. In adults,
sporadic MTC accounts for 65% to 75% of MTC (36), but in the
pediatric population, sporadic carcinomas are exceedingly rare;
the vast majority of MTC diagnosed in childhood is hereditary
(37,38). Hereditary MTC can occur independently as familial
MTC (FMTC). It can also occur as part of a triad in the multiple
endocrine neoplasia (MEN) syndromes with
pheochromocytoma and primary hyperparathyroidism in
MEN2A, or with pheochromocytoma, marfanoid habitus, and
mucosal neuromas with MEN2B. As such, it is nearly always the
first component of the MEN2 phenotypes. Both of these
syndromes are related to selected mutations of the RET proto-
oncogene receptor tyrosine kinase (39). The MTC related to
MEN2B is the most virulent, followed by that of MEN2A and
FMTC, respectively. Patients (e.g., parents and parents-to-be)
with MTC should be informed about the possibility of inheritable
cancer syndromes and offered genetic testing and counseling
as appropriate (40).
Advances in our understanding of the genotype–phenotype
relationship have allowed for the development of guidelines to
direct the timing of prophylactic total thyroidectomy, depending
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on patient-specific RET mutations. In 2009, ATA issued
evidence-based guidelines regarding the management of MTC.
Mutations are classified based on time to development of MTC
and stratified from A to D (Table 1). Risk D mutations require
prophylactic thyroidectomy within the first year of life, while the
ATA suggests surgery before age five for A, B, and C mutations,
with specific clinical criteria for exception (41). In patients with
hereditary or sporadic MTC diagnosed clinically, 80% already
have metastasized to ipsilateral and 40% to contralateral cervical
lymph nodes (42). In these cases, the ATA guidelines suggest
total thyroidectomy and central neck dissection, along with
lateral compartment lymph node dissection for clinically or
radiographically evident lymphadenopthy (41). 
Post-operatively, patients require diligent surveillance for
disease recurrence. Biochemical evidence of disease recurrence
includes new calcitonin elevation, or rapid calcitonin or
carcinoembryonic antigen (CEA) doubling time. Palpable disease
in the surgical bed or draining nodes is also indicative of
recurrent disease. In cases of suspected recurrence, imaging
with ultrasound is indicated, with the diagnosis confirmed by
FNA (40). If extra-cervical disease is suspected, computed
tomography  (and magnetic resonance imaging for the liver, in
particular) can facilitate confirmation.
Who Should be Operating on Our Children? 
Surgeons with varied specialty training, including pediatric
surgeons, otolaryngologist-head and neck surgeons, general
surgeons, and endocrine surgeons perform thyroidectomy in
pediatric patients. Some surgeon characteristics appear to be
associated with improved patient outcomes. A multidisciplinary
approach that involves pediatric endocrinologists, pediatricians,
surgeons, nuclear medicine physicians, anesthesiologists, and
pathologists is an essential part of the preoperative,
postoperative, and long-term management of children with
thyroid disease, and this is especially poignant for those pediatric
patients who undergo thyroidectomy. 
As in adults, surgeon volume appears to be directly
associated in a dose-response fashion with patient outcomes in
children undergoing thyroidectomy (43). In a study using national
data with patients and surgeons from all types of healthcare
settings, surgeon volume (in adults and children) had a greater
impact on patient outcomes than surgeon specialty (44). In-
hospital endocrine-related complication rates tended to be lower
for high-volume surgeons compared to low-volume surgeons
(5.6% vs. 10%; p=NS). Of note, these complication rates are
higher than the rates of 1-2% reported for adults undergoing
similar procedures (45). High-volume surgeons had significantly
shorter length of hospital stay (1.5 vs. 2.1 days; p<0.05) and
costs ($12 474 vs. 15 662; p<0.05) than low-volume surgeons.
The challenge in pediatric endocrine surgery is that overall
experience is limited because pediatric endocrine diseases
requiring operative intervention are relatively rare. These findings
suggest that surgeons with the best outcomes sustain their
experience by operating on children and adults.
In a literature review examining over 20 case series reports
on a total of 1800 pediatric patients, rates of permanent recurrent
laryngeal nerve injury and permanent hypoparathyroidism were
lowest in operations by high-volume thyroid surgeons (46). The
reported range of complication rates was considerable: nerve
injury rates ranged from 0% to 40%, and hypoparathyroidism
rates varied from 0% to 32%. The authors go on to note, “all
surgery should be performed by high-volume, experienced
endocrine, pediatric, and head and neck surgeons”.  In a review
article supporting thyroidectomy as the optimal treatment for
pediatric Graves’ disease, Lee et al. (47) suggested that patients
travel outside their local area if necessary to find surgeons with
extensive experience in pediatric thyroidectomy.
Published guidelines, including the ATA Management
Guidelines for Patients with Thyroid Nodules and Differentiated
Thyroid Cancer and the National Comprehensive Cancer
Network (NCCN) Clinical Practice Guidelines in Oncology, are
clear in acknowledging the importance of surgeon volume for
patient outcomes in adults undergoing thyroidectomy (48,49).
Fewer studies have examined the effect of surgeon volume on
surgical outcomes specifically among pediatric patients. The ATA
Medullary Thyroid Cancer Management Guidelines address the
role of surgeon experience in pediatric outcomes, asserting that
children undergoing thyroidectomy have higher complication
rates than adults, and have better outcomes when operated on
by high-volume surgeons (41). 
The adoption of these recommendations has been
evidenced by recent reports describing the experience of
hospitals with significant experience in pediatric
thyroidectomy. These reports highlight the benefits of
increased volume at both the surgeon and institutional level
(50,51). High-volume centers are more likely to have
systematic approaches to the pre-operative workup and post-
operative care of these patients, as well as early involvement
of dedicated pediatric and endocrine specialists. Recently,
experience with these multidisciplinary, team-based
approaches has been described; however, an improvement in
outcomes has yet to be proven (52).
Surgeon volume appears to be the most important and
robust predictor of pediatric outcomes after thyroidectomy, and
it appears to be independent of the effect of surgeon specialty.
Ensuring access to high-volume surgeons requires a
multidisciplinary approach involving parents, pediatricians, and
pediatric endocrinologists (53). For example, high-volume
surgeons need to work with pediatricians in the management of
children with postoperative hypocalcemia, which is not
uncommon after thyroidectomy. The effects of postoperative
complications in children are particularly poignant, as they can
have profound effects on physical and psychosocial
development as well as quality of life for decades afterward.
Collaboration between high-volume pediatric surgeons and
(adult) thyroid surgeons, parents, and pediatricians is likely to
optimize patient outcomes.
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